Drug delivery and protection solutions leader Aptar Pharma, a division of AptarGroup, Inc. (NYSE: ATR), has announced the strategic acquisition of Munich-based life science firm PULMOTREE.
The acquisition accelerates the development, industrialization, and commercialization of PULMOTREE’s proprietary Kolibri™ Non-Propellant Liquid Inhaler (NPLI) platform. Building on an exclusive collaboration established in 2024, the transaction enables Aptar Pharma to expand its footprint in next-generation pulmonary drug delivery, supporting complex molecules and biologics.
Following the acquisition, Aptar Pharma will integrate Pulmotree’s breath-triggered mesh aerosolization technology across its end-to-end drug development capabilities, leveraging internal expertise from Nanopharm, Noble, and Aptar Digital Health.
Key Deal Structure & Strategic Highlights:
- Technology Integration: Incorporates Pulmotree’s award-winning Kolibri™ platform—featuring advanced connectivity and breath-guidance features—into Aptar’s global respiratory portfolio.
- Value Chain Expansion: Combines device technology with Aptar’s analytical, regulatory, manufacturing, and patient onboarding services to deliver end-to-end finished solutions.
- Target Market: Enhances solutions for pharmaceutical partners delivering complex inhaled therapies and biologics.
“The acquisition of PULMOTREE is an important step in expanding Aptar Pharma’s leadership in respiratory drug delivery and broadening the opportunities we can address with our pharmaceutical partners,” said Gael Touya, President and CEO of Aptar. “Kolibri™ brings a differentiated technology with the potential to support increasingly complex inhaled therapies.”
“Joining Aptar is the natural next step on our shared path,” added Ulf Krüger, CEO of PULMOTREE. “This acquisition provides continuity in our technology, now backed by the reach and resources of a global organization.”
